Biopharmaceutical firm Celgene is set to apply to the US Food and Drug Administration for approval of its CAR-T liso-cel treatment for lymphoma during Q4 and for its CAR-T ide-cel therapy for multiple myeloma during Q1 2020, the company revealed in its Q2 earnings report. The two treatments are designed to treat patients with relapsed or refractory forms of non-Hodgkin lymphoma, a cancer that affects white blood cells.
Biopharmaceutical firm Celgene is set to apply to the US Food and Drug Administration for approval of its CAR-T liso-cel treatment for lymphoma during Q4 and for its CAR-T ide-cel therapy for multiple myeloma during Q1 2020, the company revealed in its Q2 earnings report. Trials for the liso-cel therapy saw four out of six patients with secondary central nervous system lymphoma achieve complete responses, while 2017 data showed that 68 patients achieved a 75% response rate and 56% of patients had a complete response rate.